Using Radioactive Antibodies to Treat B-Cell Lymphoma

A method for treating B-cell lymphoma by using radioactive antibodies to target cancer cells without destroying the patient's bone marrow.

What it covers

This patent describes a three-step process to treat B-cell lymphoma using antibodies that target the CD20 protein on cancer cells. First, a small amount of radioactive antibody is injected to image the patient and see where the drug goes. Second, a dose of unlabeled antibody is given to block non-tumor binding sites, ensuring the radioactive dose hits the cancer rather than healthy tissue. Finally, a therapeutic dose of radioactive antibody is administered at a level high enough to kill cancer cells but low enough to avoid damaging the bone marrow, which eliminates the need for a stem cell transplant.

What it doesn't cover

• —Does not cover treatments that require hematopoietic stem cell replacement.
• —Does not cover antibodies that do not target the CD20 antigen.
• —Does not cover non-radioactive immunotherapy methods.
• —Does not cover the manufacturing process of the antibodies themselves.

The clever bit

The innovation is the pre-treatment step using unlabeled antibodies to saturate non-specific binding sites, which allows for a more precise and safer delivery of the radioactive payload to the tumor.

Why it matters

This patent provided the foundation for Bexxar, a landmark radioimmunotherapy drug. By allowing for effective treatment without the harsh side effects of bone marrow destruction, it changed how doctors approached non-Hodgkin's lymphoma, moving toward more targeted, less toxic therapies.

Real-world examples

• 1.Bexxar (tositumomab and iodine I-131 tositumomab)